Editorial: Combination cytokine blockade: The way forward in therapy for rheumatoid arthritis?

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 14-16

  Taylor, Peter C ^a   Williams, Richard O ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; STROMELYSIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BISPECIFIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; BIOLOGICAL THERAPY; CELL WALL; EFFECTOR CELL; HELPER CELL; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; INFLAMMATORY CELL; NONHUMAN; OBSERVATIONAL STUDY; PLEIOTROPY; PROTEIN ENGINEERING; REVIEW; RHEUMATOID ARTHRITIS; TH17 CELL; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-17; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919940937     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38893     Document Type: Review

References (19)

1. Feldmann M, Maini RN,. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245-50.
2. Fischer JA, Heuber AJ, Wilson S, Galm M, Baum W, Kitson C, et al. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015; 67: 51-62.
3. Korn T, Bettelli E, Oukka M, Kuchroo VK,. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
4. Miossec P, Korn T, Kuchroo VK,. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
5. Tesmer LA, Lundy SK, Sarkar S, Fox DA,. Th17 cells in human disease. Immunol Rev 2008; 223: 87-113.
6. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S,. Type 17 T helper cells: origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009; 5: 325-31.
7. Pickens SR, Volin MV, Mandelin AM, Kolls JK, Pope RM, Shahrara S,. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010; 184: 3233-41.
8. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963-70.
9. Gullick NJ, Evans HG, Church LD, Jayaraj DM, Filer A, Kirkham BW, et al. Linking power Doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLoS One 2010; 5: e12516.
10. Shen H, Goodall JC, Hill Gaston JS,. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 1647-56.
11. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010; 62: 2876-85.
12. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54: 1122-31.
13. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO,. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp Med 2008; 205: 2491-7.
14. Aerts NE, de Knop KJ, Leysen J, Ebo DG, Bridts CH, Weyler JJ, et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 2010; 49: 2264-72.
15. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71: 1741-8.
16. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077-81.
17. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 38-47.
18. Koenders MI, Lubberts E, van de Loo FA, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, et al. Interleukin-17 acts independently of TNF-α under arthritic conditions. J Immunol 2006; 176: 6262-9.
19. Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011; 63: 2329-39.